United States: Stakeholders Say Biosimilars Names Should Be Meaningful And Memorable

Last Updated: December 2 2015
Article by Irena Royzman and Jacob F. Siegel

FDA has received comments from more than 170 groups on its proposal for naming biosimilars. Biosimilar makers, insurers and pharmacies largely oppose distinct nonproprietary names (also known as proper names) for biosimilars. By contrast, innovators (including those that develop biosimilars), healthcare providers and patient advocacy groups view them as critical to ensuring patient safety. However, most stakeholders in both camps urged FDA to use meaningful suffixes to distinguish biosimilars from originator products rather than suffixes "devoid of meaning." FDA proposed to add meaningless suffixes to the nonproprietary names of originator products to address concerns of biosimilar makers that distinguishable names will discourage adoption of biosimilar products. But biosimilar makers expressed concern that such meaningless suffixes will lead to a variety of errors and ultimately endanger public safety. FDA may now revisit its proposal given the largely uniform preference of innovators and biosimilar makers alike for meaningful and memorable nonproprietary names, such as those that identify the manufacturer of the biologic.

Under FDA's proposal, nonproprietary names would consist of the core nonproprietary name of the originator product plus a distinct four-letter suffix for originator products and biosimilars. For instance, FDA proposed to assign Sandoz's Zarxio, the only approved U.S. biosimilar, the nonproprietary name "filgrastim-bflm." Sandoz's biosimilar currently has the placeholder name "filgrastim-sndz," associating the product with Sandoz, its manufacturer. On the originator side, Zarxio is a biosimilar of Amgen's Neupogen, currently named "filgrastim." Under FDA's proposal, Neupogen would be assigned the name "filgrastim-jcwp" filgrastim plus a distinct suffix of four random lowercase letters. Unlike "sndz," the suffixes proposed by FDA would be neither meaningful nor memorable. Stakeholders, including Sandoz and Amgen, urged FDA to reconsider its naming scheme and adopt meaningful and therefore memorable suffixes instead of random ones.

Amgen, an innovator and biosimilar maker, explained that "the suffix should be meaningful (by identifying the sponsor) and consistent across the product sponsor's portfolio." According to Amgen, "[s]uch a naming convention would help prescribers and patients with product identification, thereby avoiding inadvertent substitution and fostering accurate attribution of adverse events." Amgen also noted that assigning a meaningful suffix such as "-amgn" or "-sndz" is more appropriate since the names "will be used by people (as opposed to just machines)."

Sandoz expressed concern that "the use of random consonants will endanger public safety." Mylan, a biosimilar maker, said that random suffixes may have "the perverse effect of increasing medication errors and impairing pharmacovigilance." Sandoz stated that the random suffixes would "inevitably lead to adverse event reports that cannot be attributed to a specific manufacturer, or are attributed to the wrong manufacturer". Sandoz also noted that a suffix such as "-sndz" does not confer any market advantage since "it will simply be interpreted to represent the company who makes the product" – information that is already associated with the product in FDA-approved packaging. Teva, another biosimilar maker, stressed that "meaningful names also are easier to remember, both for busy healthcare providers and especially for patients." As a result, Teva stated that "the use of meaningful names, including ones tied to the name or ownership of the licensee, seem more likely to facilitate accurate and useful adverse event reporting."

Healthcare providers and patient advocacy groups stressed the importance of memorable names. The Biologics Prescribers Collaborative (BPC) and professional organizations with biologics prescribers, such as the American College of Rheumatology, Alliance for Patient Access, American Association of Clinical Endocrinologists among others, stated: "our experience as biologics prescribers tells us that the suffix must be memorable, which cannot be easily accomplished when it is meaningless." BPC explained that a "randomized four-letter code may complicate the achievement of FDA's goal to improve pharmacovigilance and prevent inadvertent substitution." BPC emphasized that the use of meaningful suffixes reflective of the name of the manufacturer of the biologic, such as "-sndz," meets the needs of "biologics prescribers in day-to-day human interactions with patients, pharmacists, and other health care professionals."

Pharmacies and insurers also preferred suffixes with meaning to the ones proposed by FDA. CVS Health stated that a "random meaningless four-letter suffix ... could increase the rate of prescribing and dispensing errors compared to use of a naming convention in which the name is composed of the same 'core name' plus a meaningful four-letter suffix." Blue Cross Blue Shield Association also favored "using a suffix with meaning, derived from the manufacturer's name." The Association was concerned that "the use of suffix without meaning logic may lead to arbitrary and/or erroneous usage of biological products."

Innovator companies also urged FDA to adopt meaningful and memorable suffixes rather than random ones. Genentech, a developer of antibody products, stressed that memorable suffixes "will increase transparency and result in more well-informed and safe use of medicines." Pfizer, an innovator and biosimilar maker, explained that "although a randomly assigned letter suffix would be better than no unique identifier, Pfizer does not believe a random suffix would achieve accurate and efficient reporting as easily as a meaningful suffix." Pfizer also stated that if the FDA ultimately adopts random suffixes instead of meaningful ones, the suffix it adopts should be the same across a company's biological products "such that over time it will become associated with the company and make accurate reporting easier." Allergan, an innovator and biosimilar maker, explained that "the designation of a suffix that is the same for all of a license holder's products would reduce the number of suffixes the health care professionals must remember, facilitating the appropriate and correct use of the suffixes."

Given the many practical reasons not to use random suffixes and the largely uniform preference of innovators and biosimilar makers alike for meaningful and therefore memorable suffixes, FDA may reconsider its naming approach and adopt meaningful suffixes to distinguish biosimilar and originator products.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.